Persistence with hepatitis C therapy in the Department of Veterans Affairs

Journal of Clinical Pharmacy and Therapeutics

Volumn 33, Issue 3, 2008, Pages 251-261

  Iqbal, S U ^a   Cunningham, F ^b   Lee, A ^c,d   Miller, D R ^a,b   Li, N C ^b   Cheung, R ^e,f   Kazis, L ^a,b  

^a BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c Sungkyunkwan University   (South Korea)

^d NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^e VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^f STANFORD UNIVERSITY   (United States)

Author keywords

Hepatitis; Pegylated interferons; Persistence; Ribavirin; Veterans Affairs

Indexed keywords

ANTIDEPRESSANT AGENT; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RIBAVIRIN;

ADULT; ARTICLE; COHORT ANALYSIS; COMBINATION CHEMOTHERAPY; DRUG WITHDRAWAL; FEMALE; HEALTH CARE SYSTEM; HEPATITIS C; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIVIRAL AGENTS; COHORT STUDIES; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS C; HUMANS; INTERFERON ALFA-2A; INTERFERON ALFA-2B; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PATIENT DROPOUTS; POLYETHYLENE GLYCOLS; RETROSPECTIVE STUDIES; RIBAVIRIN; UNITED STATES; UNITED STATES DEPARTMENT OF VETERANS AFFAIRS;

EID: 43049090822     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/j.1365-2710.2008.00912.x     Document Type: Article

References (26)

1. Williams I (1999) Epidemiology of hepatitis C in the United States. The American Journal of Medicine, 107, 2S 9S.
2. Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ (2006) The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Annals of Internal Medicine, 144, 705 714.
3. Strader DB, Wright T, Thomas DL, Seeff LB (2004) Diagnosis, management, and treatment of hepatitis C. Hepatology, 39, 1147 1171.
4. Sharieff KA, Duncan D, Younossi Z (2002) Advances in treatment of chronic hepatitis C: 'Pegylated interferons'. Cleveland Clinic Journal of Medicine, 69, 155 159.
5. Muir AJ, Bornstein JD, Killenberg PG (2004) Peginterferon Alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-hispanic whites. The New England Journal of Medicine, 350, 2265 2271.
6. Fried MW, Shiffman ML, Reddy KR et al. (2002) Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection. The New England Journal of Medicine, 347, 975 982.
7. Manns MP, McHutchison JG, Gordon SC et al. (2001) Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. The Lancet, 358, 958 965.
8. Zeuzem S, Feinman SV, Rasenack J et al. (2000) Peginterferon alfa-2a in patients with chronic hepatitis C. The New England Journal of Medicine, 343, 1666 1672.
9. McHutchison JG, Manns M, Patel K et al. (2002) Adherence to combination therapy enhances sustained response in genotype-1 infected patients with chronic hepatitis C. Gastroenterology, 123, 1061 1069.
10. Brau N, Bini EJ, Currie S et al. (2006) Black patients with chronic hepatitis C have a lower sustained viral response rate than non-Blacks with genotype 1, but the same with genotype 2/3, and this is not explained by more frequent dose reductions of interferon and ribavirin. Journal of Viral Hepatitis, 13, 242 249.
11. Lamb M, Martin N (2002) Weight-based versus fixed dosing of peginterferon (40KD) alfa-2a. Annals of Pharmacology, 36, 933 935.
12. Selim AJ, Fincke G, Ren XS, Lee AF, Rogers W, Miller DR, Kazis LE (2002) The Comorbidity Index. In : Davies M (ed Measuring and managing health care quality, 2nd edn. New York, NY : Aspen Publishers, 91 94.
13. Iqbal SU, Francesca C, Lee A, Miller DR, Law AW, Kazis LE (2005) Persistence with hepatitis C therapy in the Department of Veterans Affairs. 56th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) #1196, 11-15 November San Francisco, CA, USA.
14. ® in patients not responding to prior peginterferon alfa-2b/ribavirin (RBV) combination therapy - efficacy analysis of the 12-week induction period of the REPEAT study. 56th Annual Meeting of the American Association for the Study of Liver Diseases (56th AASLD) Abstract 72557. 11-15, November San Francisco, CA, USA.
15. Hadziyannis SJ, Sette H Jr., Morgan TR et al. (2004) Peginterferon- alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Annals of Internal Medicine, 140, 346 355.
16. Davis GL, Wong JB, McHutchison JG, Manns MP, Harvey J, Albrecht J (2003) Early virological response to treatment with pegylated interferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology, 38, 645 652.
17. Muir AJ, Provenzale D (2002) A descriptive evaluation of eligibility for therapy among veterans with chronic hepatitis C virus infection. Journal of Clinical Gastroenterology, 34, 268 271.
18. El-Seraj HB, Kunik M, Richardson P, Rabeneck L (2002) Psychiatric disorders among veterans with hepatitis C infection. Gastroenterology, 123, 476 482.
19. Davis GL (2002) Monitoring of viral levels during therapy of hepatitis C. Hepatology, 36, S145 S151.
20. Bruno R, Sacchi P, Ciappina V, Zochetti C, Patruno S, Maiocchi L, Filice G (2004) Viral dynamics and pharmacokinetics of peginterferon alpha-2a and peginterferon alpha-2b in naive patients with chronic hepatitis C: a randomized, controlled study. Antiviral Therapy, 9, 491 497.
21. Hoffman-La Roche Inc (2002) Pegasys [package insert]. Nutley, NJ : Hoffman-La Roche Inc.
22. Schering-Plough Corporation (2002) PEG-Intron [package insert]. Kenilworth, NJ : Schering-Plough Corporation.
23. Modi MW, Lamb MW, Shiomi M. Peginterferon alfa-2a (40KD) (2003) A potent long-acting form of interferon alfa-2a for the treatment of hepatitis C. Polymer Drugs in the Clinical Stage. New York : Kluwer Academic/Plenum Publishers.
24. Available at: http://dukemednews.duke.edu/global/download.pdf?ids=7050, accessed on 11 January 2006.
25. Schaefer M, Hinzpeter A, Mohmand A et al. (2007) Hepatitis C treatment in 'difficult-to-treat' psychiatric patients with pegylated interferon-alpha and ribavirin: Response and psychiatric side effects. Hepatology, 46, 991 998.
26. Smith SR, Wahed AS, Kelley SS, Conjeevaram HS, Robuck PR, Fried MW (2007) Assessing the validity of self-reported medication adherence in hepatitis C treatment. Annals of Pharmacotherapy, 41, 1116 1123.